Back To: Home

CLICK HERE FOR WHAT'S NEW IN:
 




 

A new model for NAFLD
November 2016
SHARING OPTIONS:

SANTA CLARA, Calif.—Crown Bioscience has reported on a milestone in its development of a model of non-alcoholic fatty liver disease (NAFLD). The model in question was created by PreClinOmics, a CrownBio company, with its proprietary FATZO model for obesity and type 2 diabetes, which is a spontaneously hyperglycemic model. CrownBio presented its data on the new model at this year's Discovery on Target meeting.
 
“The new model complements our NHP model of NAFLD and non-alcoholic steatohepatitis, creating a continuum of in-vivo platforms that enables us to provide our clients with end-to-end preclinical support for their CVMD research,” said Dr. Jim Wang, senior vice president of cardiovascular and metabolic disease (CVMD) research at CrownBio. “It can be used as a translational tool to study novel compounds in late-stage drug discovery.”

Back



PAGE UTILITIES


CONTACT US
DDNEWS
Published by Old River Publications LLC
19035 Old Detroit Road
Rocky River, OH USA 44116
Ph: 440-331-6600  |  Fax: 440-331-7563
 
© Copyright 2017 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.